Vical receives patent for gene based, non viral delivery of IL-2
With Vical's method, a highly stable ring of DNA is formulated with a cationic lipid to produce a non-viral delivery method for protein-producing genes. Once delivered, the genes may cause the malignant cells to produce IL-2 protein, which stimulates the immune system to attack and destroy the tumor. Recombinant IL-2 protein, an approved anti-cancer agent for the treatment of advanced kidney cancer and melanoma, is frequently associated with serious side effects when administered systemically.
According to Vical chief operating officer Deirdre Y. Gillespie, current uses of IL-2 systemic protein therapy have been limited by its toxicity. "Many potential patients are unable to tolerate the recommended doses, and some doctors have been reluctant to prescribe the treatment," she said. "We believe our patented delivery method may overcome that problem and make IL-2 more broadly available for cancer patients."
Vical is currently conducting Phase II clinical trials of Leuvectin, the company's IL-2 product candidate, as a potential treatment for renal and prostate cancers, Gillespie added. The company was issued U.S. Patent No. 5,641,665 for the specific construct of Leuvectin in 1997.
Vical Inc. is focused on the development of pharmaceutical product candidates based on its patented gene delivery technology. A number of therapeutic and vaccine product candidates are currently under development for the prevention or treatment of cancer, infectious diseases, and metabolic disorders by Vical and its collaborative partners.
For more information: Vical Inc., 9373 Towne Centre Dr., Ste. 100, San Diego, CA 92121-3088. Tel: 858-646-1100. Fax: 858-646-1150.
Edited by Jim Pomager
Assistant Editor, Drug Discovery Online
Source: Vical Inc.